The purpose of the study is to find out which treatment is better at helping children with this type of arthritis reach a state of minimal disease activity after six months, meaning their symptoms are much improved and under better control. The study will look at whether children taking one of the three non-TNFi medications do better than those taking a second TNFi medication. The study will also measure how the different treatments affect pain, tiredness, and the ability to move around, as well as overall disease activity.

Children taking part in the study will be assigned to receive one of the four treatment approaches and will continue treatment for twelve months. During this time, they will have regular check-ups to see how well the medication is working and to monitor for any side effects. The study will measure disease activity at six months and again at twelve months to see how well each treatment controls the arthritis over time. Children in the study must be at least two years old but under eighteen years old, weigh at least ten kilograms, and have active arthritis despite having tried a TNFi medication for at least three months.

The study will monitor how the body processes the medication, a process known as pharmacokinetics. It will also look at how well the drug works to reduce symptoms and whether it causes any side effects. During the course of the study, participants will be observed over several weeks to track changes in their condition and any potential reactions to the treatment.

The study is an open-label extension, which means that all participants know which medication they are receiving during this phase. Participants will continue to take the medication over an extended period to monitor for any adverse events, which are unexpected or unpleasant side effects. The research also looks at the occurrence of uveitis, an inflammation that can happen inside the eye, to ensure the treatment is safe for long-term use in young people.

Two different RSV vaccines will be used in the study: Arexvy and Abrysvo. Both vaccines are given as a single injection into the muscle. The purpose is to determine if the medications used to treat inflammatory rheumatic disease affect how well the body develops protection after receiving the RSV vaccine.

Participants will receive one dose of the RSV vaccine and will have blood samples taken before and after vaccination to measure their body’s immune response. The study will also monitor any side effects that may occur after vaccination. This information will help healthcare providers better understand how these treatments influence vaccine effectiveness in patients with inflammatory rheumatic disease.

The purpose of the study is to determine if deucravacitinib is more effective than a placebo in treating JPsA in children and adolescents aged 5 to 18. Participants will take the medication or placebo orally over a period of time, and researchers will monitor how long it takes for the first flare-up of the disease to occur. The study will also assess how much the disease improves, how many participants experience a reduction in symptoms, and how well the medication is tolerated, including its taste and ease of swallowing.

Throughout the study, researchers will keep track of any side effects and monitor the overall safety of deucravacitinib. They will also evaluate the amount of the medication in the body and its impact on the disease. The trial aims to provide valuable information on the effectiveness and safety of deucravacitinib for managing Juvenile Psoriatic Arthritis in young patients.

The purpose of this study is to explore a new strategy for using anakinra in children with sJIA. The study aims to determine if using a specific marker in the blood, called IL-18, can help guide the treatment process. This approach may help reduce the number of injections needed to keep the disease inactive during the first year of treatment. The study will involve an initial phase where patients receive anakinra, followed by a phase where the treatment is gradually reduced and stopped, depending on the patient’s response.

Throughout the study, researchers will monitor the number of injections required, the number of patients who achieve disease remission without medication, and any potential side effects. The goal is to find a more efficient way to manage sJIA, potentially reducing the treatment burden for patients while maintaining effective disease control.

The purpose of the study is to understand how sarilumab behaves in the body of children and adolescents aged 1 to 17 years with sJIA. This will help determine the right dose and schedule for treating this condition. Participants in the study will receive repeated doses of sarilumab, and the study will include an initial phase followed by an extension phase. The study will monitor how the body processes the medication and will also look at the safety and tolerability of the treatment over time.

Throughout the study, researchers will assess various health indicators, such as the number of joints affected by arthritis and overall well-being, to see how the treatment impacts the condition. The study will also track any side effects experienced by participants. The goal is to gather comprehensive information to help improve treatment options for children and adolescents with sJIA.

The purpose of the study is to evaluate the safety and effectiveness of switching between the original and biosimilar versions of these medications in children with JIA who are in clinical remission, meaning their disease activity is low or inactive. Participants in the study will be randomly assigned to receive either the original or biosimilar version of the medication. The study will last for a total of 18 months, during which the participants’ health and response to the medication will be monitored closely.

Throughout the study, the main goal is to see how many children remain in clinical remission after switching between the original and biosimilar medications. This will help determine if the biosimilar versions are as effective and safe as the original medications. The study aims to provide valuable information that could help improve treatment options for children with Juvenile Idiopathic Arthritis.

The purpose of the study is to compare the effects of continuing stable treatment with Methotrexate and TNFi against two different strategies for withdrawing these treatments. The study aims to understand how these strategies affect the risk of disease flares, which are periods when symptoms worsen. Participants will be monitored over a period of time to see if they experience any flares and how quickly they can return to an inactive state of the disease after a flare.

Throughout the study, researchers will also track changes in disease activity and any side effects or unexpected reactions to the treatments. The study will last for several years, with participants being followed up for at least 12 months to gather comprehensive data on the effectiveness and safety of the treatment strategies. This research aims to optimize treatment plans for young patients with Juvenile Idiopathic Arthritis who are in sustained remission.

The purpose of the study is to compare the effectiveness of these two treatment strategies in achieving clinical remission, which means the absence of active disease symptoms, over a period of 12 months. Participants in the study will receive either the Step-up or Step-down treatment plan, and their progress will be monitored to see which approach is more effective in managing the symptoms of juvenile idiopathic arthritis. The study will also look at how many patients achieve a state of inactive disease at any point during the study.

Participants will be children newly diagnosed with juvenile idiopathic arthritis who have not previously been treated with disease-modifying antirheumatic drugs (DMARDs), except for one non-steroidal anti-inflammatory drug (NSAID). The study will last for a maximum of six months for each participant, and the treatments will be administered through subcutaneous injections, which means the medication is injected under the skin. The trial aims to provide valuable insights into the best treatment strategies for managing juvenile idiopathic arthritis in children.

The purpose of the study is to determine if baricitinib is safe and effective for children with JIA. Participants will receive the medication in the form of a tablet or oral suspension, which means it is taken by mouth. The study will monitor the participants over a period to observe any side effects and to see how well the medication works in managing the symptoms of JIA.

Throughout the study, some participants may receive a placebo, which is a substance with no active medication, to compare the effects of baricitinib. The study aims to gather information on the number of participants who experience serious side effects or need to stop taking the medication permanently. This information will help in understanding the long-term use of baricitinib in treating JIA in children.

Participants in the study will be randomly assigned to one of two groups. One group will receive the joint injections along with their TNFi treatment, while the other group will receive only the TNFi treatment. The study will be conducted over a period of time, during which the health of the participants will be monitored to see if the joint injections help in maintaining inactive disease without the need for additional glucocorticoid use.

The trial aims to provide valuable information on whether adding joint injections to the standard TNFi treatment can improve outcomes for children with JIA. This could potentially lead to more personalized treatment strategies for managing this condition. The study is designed to ensure that all participants are carefully monitored and assessed by healthcare professionals throughout the trial period.

Participants in the study will receive tofacitinib in either a film-coated tablet or an oral solution form. The study will last for up to 120 days, during which participants will take the medication daily. Throughout the study, regular check-ups will be conducted to monitor the participants’ health, including their growth and physical development. These check-ups will involve standard laboratory tests and assessments of any side effects that may occur.

The study will also evaluate how well the medication is working by looking at various health indicators. These include the number of joints with active arthritis, the level of inflammation in the body, and overall physical function. Additionally, the study will assess the participants’ overall well-being and any changes in their arthritis symptoms. The goal is to gather comprehensive information on the long-term use of tofacitinib in managing the symptoms of JIA in children.

The purpose of the study is to evaluate how effective Ixekizumab is in treating these types of arthritis in children. The study will involve giving the medications through a subcutaneous injection, which means the medicine is injected under the skin. Children participating in the study will receive either Ixekizumab or Adalimumab, and their progress will be monitored over time to see how well the treatments work in reducing symptoms of arthritis.

Throughout the study, researchers will observe the safety and tolerability of the treatments, ensuring that they are safe for use in children. The study aims to provide valuable information on how these medications can help manage juvenile idiopathic arthritis, potentially improving the quality of life for children affected by these conditions.

Participants in the study will receive either Upadacitinib or Tocilizumab over a period of time. The study will monitor changes in the disease’s activity and any adverse events that may occur. The study will also look at how the drugs are processed in the body. The trial is designed to provide valuable information on the safety and effectiveness of these treatments for children and adolescents with active Systemic Juvenile Idiopathic Arthritis.

The study will last for up to 52 weeks, during which participants will be regularly assessed to track their progress and any changes in their condition. This research aims to improve understanding and treatment options for young people living with Systemic Juvenile Idiopathic Arthritis.

Participants in the study will take the medication orally, which means they will swallow the tablets. The study will involve multiple doses of the medication, and researchers will monitor how the medication is absorbed and processed in the body. This will help determine the safety and tolerability of filgotinib in young patients. The study will also look at any side effects that may occur and how well the participants accept the tablets.

The study is designed to gather important information about the medication’s effects in children and teenagers aged 8 to less than 18 years. By understanding how filgotinib works in younger patients, researchers hope to improve treatment options for those with juvenile idiopathic arthritis. The study will continue until the end of 2024, providing valuable insights into the use of filgotinib for this condition.

The purpose of this study is to assess the long-term safety of Secukinumab in patients who have previously participated in a related study and are believed to benefit from continued treatment. Participants will receive Secukinumab through subcutaneous injections, which means the medication is injected under the skin. The study will continue for a period of up to 104 weeks, during which the safety of the treatment will be closely monitored by healthcare professionals.

Throughout the study, participants will be observed for any serious adverse events (SAEs) or adverse events (AEs), which are any unwanted effects that may occur during treatment. The study is open-label, meaning both the participants and the researchers know which treatment is being administered. This trial is designed to ensure that patients who benefit from Secukinumab can continue to receive it safely, with careful monitoring to manage any potential risks.

Participants in the study will receive multiple doses of Upadacitinib over a period of time. The study will monitor how the medication is absorbed and processed in the body, as well as any side effects that may occur. The study will also look at the long-term safety of the medication for those who continue with the treatment after the initial phase. Additionally, the study will evaluate how effective the medication is in managing the symptoms of pcJIA.

Throughout the study, researchers will also assess the taste of the oral solution form of Upadacitinib to ensure it is acceptable for children. The study aims to provide valuable information on the use of this medication in young patients with pcJIA, potentially offering a new treatment option for managing this condition.

The purpose of this study is to learn if bimekizumab is safe and how it moves throughout the body in children with these types of arthritis. The study will involve children aged 2 to less than 18 years who have active disease. Participants will receive bimekizumab injections and will be monitored over a period of time to see how the medication affects them. The study will also look at any side effects that may occur and how the children’s health changes during the study.

Throughout the study, researchers will measure the levels of bimekizumab in the blood and observe any changes in the participants’ health, including their growth and vital signs like blood pressure and heart rate. The study will also assess any reactions at the injection site and monitor for any serious side effects, such as infections or other health issues. This information will help determine the safety and effectiveness of bimekizumab for treating these types of juvenile arthritis in children.

The purpose of the study is to determine if stopping medication early, based on certain health markers, is safe and more effective than the standard practice of maintaining the same treatment for a longer period. Participants will be randomly assigned to either continue their medication or to stop it early. Throughout the study, the health of the participants will be closely monitored to see if their arthritis symptoms return, which is known as a flare-up. The study will compare the number of flare-ups and the time it takes for them to occur between the two groups.

This trial is designed to help understand if early withdrawal of medication can be a safe and effective option for children with juvenile idiopathic arthritis who are in remission. The study will use advanced techniques like imaging and multi-Omics, which involves analyzing various biological data, to guide the decision on when to stop the medication. The findings could lead to more personalized treatment plans for children with this condition.